FibroGen Can't Dodge Securities Suit Over Anemia Drug
FibroGen Inc. can't escape a securities fraud class action over the flop of a once-hyped anemia drug, as a California judge ruled the investors plausibly alleged that the company made misleading...To view the full article, register now.
Already a subscriber? Click here to view full article